为了进一步提高KRAS G12C突变患者的治疗效果，研究团队设计了一项临床试验。他们尝试将靶向药索托拉西布与传统化疗（卡铂和培美曲塞）相结合，用于治疗晚期非鳞状非小细胞肺癌患者。

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

A study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence ...

Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...

The research uncovers key genetic mutations that affect cancer treatment responses and develops a predictive tool for ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...